A Universal Strategy for Proteomic Studies of SUMO and Other Ubiquitin-like Modifiers*S

  1. Van G. Wilson
  1. From the Department of Medical Microbiology and Immunology, Texas A&M University System Health Science Center, Reynolds Medical Building, College Station, TX 77843-1114; and §Department of Chemistry, Texas A&M University, PO Box 30012, College Station, TX 77842-3012
  1. To whom correspondence should be addressed: Department of Medical Microbiology and Immunology, Texas A&M University System Health Science Center, Reynolds Medical Building, College Station, TX 77843-1114. Tel.: 979-845-5207; Fax: 979-845-3479; E-mail: Wilson{at}medicine.tamhsc.edu

Abstract

Post-translational modification by the conjugation of small ubiquitin-like modifiers is an essential mechanism to affect protein function. Currently, only a limited number of substrates are known for most of these modifiers, thus limiting our knowledge of their role and relevance for cellular physiology. Here, we report the development of a universal strategy for proteomic studies of ubiquitin-like modifiers. This strategy involves the development of stable transfected cell lines expressing a double-tagged modifier under the control of a tightly negatively regulated promoter, the induction of the expression and conjugation of the tagged modifier to cellular proteins, the tandem affinity purification of the pool of proteins covalently modified by the tagged modifier, and the identification of the modified proteins by LC and MS. By applying this methodology to the proteomic analysis of SUMO-1 and SUMO-3, we determined that SUMO-1 and SUMO-3 are stable proteins exhibiting half-lives of over 20 h, demonstrated that sumoylation with both SUMO-1 and SUMO-3 is greatly stimulated by MG-132 and heat shock treatment, demonstrated the preferential usage of either SUMO-1 or SUMO-3 for some known SUMO substrates, and identified 122 putative SUMO substrates of which only 27 appeared to be modified by both SUMO-1 and SUMO-3. This limited overlapping in the subset of proteins modified by SUMO-1 and SUMO-3 supports that the SUMO paralogues are likely to be functionally distinct. Three of the novel putative SUMO substrates identified, namely the polypyrimidine tract-binding protein-associated splicing factor PSF, the structural microtubular component α-tubulin, and the GTP-binding nuclear protein Ran, were confirmed as authentic SUMO substrates. The application of this universal strategy to the identification of the pool of cellular substrates modified by other ubiquitin-like modifiers will dramatically increase our knowledge of the biological role of the different ubiquitin-like conjugations systems in the cell.

Footnotes

  • Published, MCP Papers in Press, November 30, 2004, DOI 10.1074/mcp.M400149-MCP200

  • 1 The abbreviations used are: PML, promyelocytic leukemia; ActD, actinomycin D; FRT, Flp recombination target; F293, a human embryonic kidney 293 (HEK293) derivative cell line containing a single FRT sequence and expressing the Tet repressor gene; His-S-SUMO, N-terminal fusion of a (His)6∼S-peptide and SUMO; NEM, N-ethylmaleimide; TAP, tandem affinity purification; Tet, tetracycline; DMEM, Dulbecco’s modified Eagle medium; HRP, horseradish peroxidase; PTB, polypyrimidine tract-binding protein; PSF, PTB-associated splicing factor.

  • * This work was funded by National Institute of Health Grant CA89298 (to V. G. W.) and RR019587 (to D. H. Russell).

  • S The on-line version of this manuscript (available at http://www.mcponline.org) contains supplemental material.

    • Received October 6, 2004.
    • Revision received November 23, 2004.
| Table of Contents

This Article

  1. Molecular & Cellular Proteomics, 4, 56-72.
  1. Supplemental Data
  2. All Versions of this Article:
    1. M400149-MCP200v1
    2. 4/1/56 most recent

Classifications

Article Usage Stats

Responses

  1. Submit a Letter to the Editor
  2. No responses published